Cancer Treatments Access Extension

This trial aims to provide ongoing access to cancer treatments for individuals benefiting from a specific Exelixis-sponsored study. The study includes treatments such as Cabozantinib and Zanzalintinib, either alone or combined with other medications. It targets those who continue to see positive results from their current study treatment and cannot access it locally. Participants should be able to continue with the treatment plan and must not have been disqualified from their initial study. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of these treatments to a wider population.

Research has shown that cabozantinib is generally safe to manage. Common side effects include diarrhea and tiredness, affecting more than 25% of patients. Some patients may also experience low calcium levels, though severe cases are rare. Cabozantinib can cause heart problems, so regular check-ups are important.

Early findings suggest that zanzalintinib has a safety profile similar to other treatments targeting multiple pathways in cancer cells. Experts closely monitor its safety to protect participants. However, its safety and effectiveness are not fully confirmed yet.

Unlike the standard treatments for cancer, which often involve chemotherapy or radiation, Cabozantinib and Zanzalintinib offer a fresh approach by targeting specific proteins that help tumors grow and spread. Cabozantinib works by inhibiting the activity of tyrosine kinases, which are enzymes involved in tumor growth and blood vessel development. Zanzalintinib, on the other hand, is designed to block the VEGFR, a receptor that plays a crucial role in the formation of blood vessels that supply the tumor. Researchers are excited about these treatments because they might not only be more effective but also potentially have fewer side effects compared to traditional cancer therapies.

Research has shown that cabozantinib, one of the treatments in this trial, holds promise for cancer treatment. Specifically, studies found that after 12 months, 85.7% of patients treated with cabozantinib remained alive, compared to 75.6% with other treatments. More than 40% of patients experienced tumor shrinkage. Additionally, cabozantinib was associated with a 34% decrease in the rate of disease progression or death. These findings suggest that cabozantinib can be an effective option for treating cancer. Participants in this trial may receive cabozantinib alone or in combination with other agents, depending on their study treatment group.⁶⁷⁸⁹¹⁰